Tarsus Pharmaceuticals, Inc. balance sheet TARS

Annual Quarterly

As of Sep 30, 2026, Tarsus Pharmaceuticals, Inc. had total assets of $505.5 million and total liabilities of $401.5 million. Total assets were down 5.4% from a year earlier. Stockholders' equity was $104.0 million. It held $316.3 million in cash and investments against $89.4 million of total debt, net cash of $226.9 million. The current ratio, current assets divided by current liabilities, was 1.96.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Assets
Cash
137
+21.1%
184
+93.7%
95
-57.8%
225
+213.9%
72
-58.2%
171
+1.9%
168
Short-term investments
173
-40.1%
234
+18.9%
197
+7778.0%
2
-98.3%
145
+29996.5%
0
—
Long-term investments
7
+122.7%
4
+29.0%
3
+375.4%
1
+70.1%
0
—
—
Cash and investments
316
-21.9%
421
+43.1%
294
+29.1%
228
+4.9%
217
+26.5%
172
+2.2%
168
Receivables
100
+38.3%
85
+81.9%
47
+181.3%
17
—
—
—
Inventory
5
+34.5%
4
+66.9%
3
-15.7%
3
—
—
—
Total current assets
445
-11.2%
523
+46.6%
357
+39.3%
256
+13.6%
225
+28.1%
176
+3.1%
171
Property and equipment, net
21
+260.6%
12
+404.1%
2
+57.6%
1
+53.4%
1
+26.8%
1
+37.8%
1
Total assets
505
-5.4%
562
+49.1%
377
+42.0%
265
+16.5%
228
+27.4%
179
+4.0%
172
Liabilities and equity
Accounts payable
35
16
—
—
—
—
—
Total current liabilities
227
+94.0%
136
+68.3%
81
+118.2%
37
+139.4%
15
+34.4%
11
+113.1%
5
Total liabilities
401
+101.3%
219
+43.5%
152
+122.6%
69
+95.9%
35
+187.1%
12
+103.2%
6
Stockholders' equity
104
-69.0%
343
+53.0%
225
+14.0%
197
+2.1%
193
+15.7%
167
+0.5%
166
Debt
Long-term debt
73
+0.9%
72
+0.8%
72
+140.9%
30
+53.4%
19
—
—
Lease liabilities
16
+61.3%
11
+1643.3%
1
-68.2%
2
+115.2%
1
-25.5%
1
+43.7%
1
Total debt
89
+8.4%
83
+14.6%
72
+128.3%
32
+56.1%
20
+1602.1%
1
+43.7%
1
Net cash
227
-29.6%
338
+52.4%
222
+13.0%
196
-0.4%
197
+15.5%
171
+2.0%
167
Ratios
Current ratio
1.96x
3.85x
4.42x
6.93x
14.61x
15.33x
31.68x
Debt to equity
0.86x
0.24x
0.32x
0.16x
0.11x
0.01x
0.01x
Return on equity
-675.03%
-19.34%
-51.46%
-68.99%
-32.19%
-8.29%
-16.15%
Return on assets
-138.92%
-11.81%
-30.65%
-51.19%
-27.25%
-7.73%
-15.59%
Book value per share
2.11
8.07
5.85
5.76
7.22
8.06
8.17
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
TARS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Irvine, CA
SEC filer status
Large accelerated filer
SEC CIK
1819790

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.